Blog
Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy
Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the tumor necrosis factor receptor (TNFR) superfamily. By activating DR5, Tigatuzumab induces apoptosis
…
17th Dec 2025
Alemtuzumab Biosimilar: Advancing CD52-Targeted Therapy
Alemtuzumab is a monoclonal antibody targeting CD52, a glycoprotein highly expressed on mature lymphocytes. By binding CD52, Alemtuzumab induces immune-mediated depletion of lymphocytes,
…
17th Dec 2025
Enavatuzumab Biosimilar: Advancing TWEAKR-Targeted Therapy in Cancer
Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as Fn14), a member of the tumor necrosis factor receptor (TNFR) family. Overexpressed in many solid tumo
…
17th Dec 2025
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars
Sacituzumab govitecan is an innovative antibody-drug conjugate (ADC) targeting Trop-2, a transmembrane glycoprotein overexpressed in many epithelial cancers. By selectively delivering a c
…
2nd Jan 2025
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy
What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
…
1st Jan 2025
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research
What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
…
1st Jan 2025
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation
Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key receptor in the immune system. By blocking CD40-CD40L interactions, Iscalimab inhibits immune activation, making it a pro
…
31st Dec 2024
Ifabotuzumab: Exploring the Role of Anti-EphA3 in Cancer Research
Ifabotuzumab is a monoclonal antibody targeting the EGFRvIII mutation, a tumor-specific variant of the epidermal growth factor receptor (EGFR). This mutation is associated with aggressive
…
31st Dec 2024
Varlilumab: Unlocking CD27’s Potential in Cancer Research
Varlilumab is a monoclonal antibody targeting CD27, a critical costimulatory receptor in the immune system. Acting as a CD27 agonist, Varlilumab enhances T-cell activation and effector fu
…
31st Dec 2024
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research
Brentuximab vedotin is a CD30-targeting antibody-drug conjugate (ADC) approved for treating CD30-positive malignancies, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (A
…
31st Dec 2024
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research
Gemtuzumab ozogamicin is a CD33-targeting antibody-drug conjugate (ADC) approved for the treatment of acute myeloid leukemia (AML). By selectively delivering a cytotoxic payload to CD33-p
…
31st Dec 2024
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research
Indatuximab ravtansine is a CD138-targeting antibody-drug conjugate (ADC) designed for the treatment of multiple myeloma and other CD138-expressing cancers. By delivering a cytotoxic payl
…
31st Dec 2024
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research
Vopratelimab is a monoclonal antibody targeting inducible T-cell costimulator (ICOS), a key receptor involved in T-cell activation and immune regulation. By selectively activating ICOS, V
…
31st Dec 2024
Targeting IL-10R: Enhancing Immune Activation in Cancer
Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma
…
12th Dec 2024
Rituximab Biosimilar: Transforming CD20-Targeted Therapy for Hematologic Malignancies
Rituximab is a monoclonal antibody targeting CD20, a cell surface protein found on B lymphocytes. By engaging immune-mediated mechanisms, Rituximab eliminates CD20-positive B cells, makin
…
12th Dec 2024
Tiragolumab Biosimilar: Enhancing Immune Checkpoint Therapy with TIGIT Inhibition
Tiragolumab is a monoclonal antibody targeting TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activity in
…
12th Dec 2024
Vibostolimab Biosimilar: Advancing Immune Activation with TIGIT Inhibition
Vibostolimab is a monoclonal antibody that targets TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activit
…
12th Dec 2024
Belantamab Biosimilar: Targeting BCMA for Multiple Myeloma Treatment
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), a protein highly expressed on malignant plasma cells in multiple myeloma (MM). By deli
…
12th Dec 2024
Pinatuzumab Biosimilar: Advancing CD22-Targeted Therapy in B-Cell Malignancies
Pinatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD22, a cell surface marker highly expressed on malignant B cells. It delivers a potent cytotoxic agent directly to CD22-
…
12th Dec 2024
Etigilimab Biosimilar: Advancing TIGIT Inhibition in Cancer Immunotherapy
Etigilimab is a monoclonal antibody targeting TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell activity in tumors. By blocking TIGIT, Et
…
10th Dec 2024
Girentuximab Biosimilar: Targeting Carbonic Anhydrase IX (CAIX) for Cancer Therapy
Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), a tumor-associated antigen overexpressed in clear cell renal cell carcinoma (ccRCC) and hypoxic tumors. By se
…
10th Dec 2024
Tesnatilimab Biosimilar: Advancing CD38-Targeted Therapy
Tesnatilimab is a monoclonal antibody targeting CD38, a transmembrane glycoprotein highly expressed on malignant plasma cells in multiple myeloma (MM) and other hematologic malignancies.
…
10th Dec 2024
Ipilimumab Biosimilar: Expanding Access to CTLA-4 Inhibition
Ipilimumab (Yervoy) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a key immune checkpoint receptor. By inhibiting CTLA-4, Ipilimumab enhances T-
…
9th Dec 2024
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies
1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive c
…
5th Dec 2024